Aquestive Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aquestive Therapeutics, Inc. (AQST) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-44.14-7.87-54.41-70.54-55.78-66.25-61.38
Depreciation & Amortization0.741.372.606.703.614.833.24
Stock Based Compensation7.102.694.386.826.580.000.00
Change in Working Capital-9.96-5.3431.30-1.73-4.41-11.128.00
Change in Accounts Receivable1.09-3.077.35-5.356.180.000.00
Change in Inventory0.73-0.99-1.74-1.580.400.000.00
Change in Accounts Payable2.78-1.022.311.23-2.210.000.00
Change in Other Working Capital-1.72-1.235.8515.69-7.950.000.00
Other Operating Activities-0.220.8010.0118.771.967.431.93
Net Cash from Operating Activities-35.76-6.38-9.82-32.98-45.46-60.21-12.99
Investing Activities
Capital Expenditures-0.16-1.002.520.91-0.520.66-1.82
Sales/Maturities of Investments0.000.00-1.500.000.000.000.00
Net Cash from Investing Activities-0.16-1.00-2.52-0.91-0.52-0.66-1.82
Financing Activities
Debt Repayment-0.02-53.63-2.030.00-22.50-50.000.00
Common Stock Issued84.7217.2613.5929.786.6939.3268.83
Common Stock Repurchased-1.10-0.010.00-0.01-0.100.000.00
Other Financing Activities0.007.119.68-0.0144.37-2.83-10.80
Net Cash from Financing Activities83.593.9711.5930.1128.4649.6058.04
Summary
Net Change in Cash47.67-3.40-0.75-3.78-17.52-11.2743.22
Cash at Beginning of Period23.8727.2728.0231.8149.3360.6017.38
Cash at End of Period71.5523.8727.2728.0231.8149.3360.60
Free Cash Flow-35.92-7.38-12.34-33.89-45.98-60.87-14.82
Supplemental Disclosures
Interest Paid7.104.606.446.448.497.346.05
Income Taxes Paid0.310.000.000.000.000.000.00